Cryosa

Executive Summary

Cryosa is a clinical-stage medical device company developing a novel, non-invasive treatment for moderate to severe obstructive sleep apnea (OSA). Current standard-of-care therapies such as continuous positive airway pressure (CPAP) suffer from poor patient adherence due to discomfort, while implantable solutions require surgery. Cryosa's technology employs targeted cryotherapy to precisely remodel the soft palate, reducing tissue collapse during sleep without masks, hoses, or implants. This outpatient procedure could dramatically improve patient compliance and quality of life. Founded in 2015 and headquartered in Maple Grove, Minnesota, the company has advanced to Phase I clinical trials. If successful, Cryosa's approach could address a significant unmet need in the $10+ billion sleep apnea market, potentially becoming a first-line therapy for the millions of patients intolerant to existing treatments.

Upcoming Catalysts (preview)

• Q3 2026Phase I trial interim safety and efficacy data75% success
• Q1 2027FDA Breakthrough Device Designation or IDE approval for pivotal trial60% success
• Q4 2026Strategic partnership with a sleep clinic network or larger medtech company50% success